Liraglutide injection

DRUG7 trials

Sponsors

Xiaojun Chen, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., The Affiliated Hospital of Qingdao University, Emirates Health Services (EHS), Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca

Conditions

Atypical Endometrial HyperplasiaBariatric SurgeryBariatric Surgery CandidateDelirium, PostoperativeFertility IssuesObeseObesityObesity, Morbid

Phase 1

Human Bioequivalence Test of Liraglutide Injection

CompletedNCT05029076

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Type 2 Diabetes

Start: 2019-05-21End: 2019-07-01Updated: 2021-08-31

A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects

CompletedNCT05225974

The Affiliated Hospital of Qingdao UniversityTherapeutic Equivalency

Start: 2021-07-16End: 2021-08-19Updated: 2022-02-07

Phase 2

Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia

WithdrawnNCT04683237

Xiaojun ChenAtypical Endometrial Hyperplasia, Fertility Issues, Obese

Start: 2021-03-20End: 2026-11-30Updated: 2024-09-26

Phase 3

Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery

RecruitingNCT06361238

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolDelirium, Postoperative

Start: 2024-11-19End: 2028-03-31Target: 260Updated: 2024-12-20

Phase 4

Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery

CompletedNCT06201819

Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. MenchacaBariatric Surgery Candidate, Obesity, Morbid, Weight Loss

Start: 2022-12-18End: 2023-05-01Updated: 2024-01-18

Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery

CompletedNCT07374445

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolBariatric Surgery, Obesity, Weight Loss

Start: 2023-09-01End: 2025-06-01Updated: 2026-01-28

Unknown Phase

POSE2.0 With GLP-1 Agonist for Obesity Management

Emirates Health Services (EHS)Obesity

Start: 2023-01-16End: 2026-01-03Target: 50Updated: 2023-01-30

Related Papers

Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial

Expert Review of Clinical Pharmacology2023-03-081 citations